News & Updates
Filter by Specialty:
Oral minoxidil may be a viable alternative to topical treatment for male pattern baldness
Low-dose oral minoxidil demonstrates comparable efficacy to 5% topical minoxidil in the treatment of androgenetic alopecia in men, offering a viable option for those who prefer oral therapy or those who poorly tolerate topical treatment, as shown in a study.
Oral minoxidil may be a viable alternative to topical treatment for male pattern baldness
13 Apr 2024
Deuruxolitinib helps restore crowning glory in alopecia areata
Pooled analyses of the phase III THRIVEAA1 and THRIVE-AA2 trials underpin the potential of the selective oral JAK* 1/2 inhibitor deuruxolitinib to effectively and safely reverse hair loss in adults with moderate-to-severe alopecia areata (AA).
Deuruxolitinib helps restore crowning glory in alopecia areata
25 Mar 2024
Lebrikizumab plus TCS improves outcomes in moderate-to-severe AD
Treatment with lebrikizumab in combination with topical corticosteroids (TCS), compared with TCS alone, results in early and sustained improvements in patient-reported outcomes (PROs) among individuals with moderate-to-severe atopic dermatitis (AD), as shown in a Japan study.
Lebrikizumab plus TCS improves outcomes in moderate-to-severe AD
23 Mar 2024
ESK-001 makes good STRIDEs for plaque psoriasis
In the phase II dose-ranging STRIDE trial presented at AAD 2024, ESK-001, a highly-selective and potentially best-in-class allosteric tyrosine kinase 2 (TYK2) inhibitor, demonstrated favourable efficacy and safety signals for the treatment of adults with moderate-to-severe plaque psoriasis.